logo
Miracle rescues offer hope, days after deadly Myanmar earthquake

Miracle rescues offer hope, days after deadly Myanmar earthquake

Yahoo03-04-2025

Two survivors have been pulled from under the rubble of collapsed buildings in Myanmar, more than five days after the country was struck by a devastating 7.7 magnitude earthquake.
The miraculous rescues of the two men offer rare moments of hope in the Southeast Asian country, where the ruling military government has announced a temporary ceasefire in operations against armed opposition groups to aid recovery efforts.
One of the rescues came in the city of Mandalay, near the quake's epicenter, where a 53-year-old man was saved by Myanmar fire officials and a Chinese rescue team on Wednesday, 125 hours after he became trapped in the debris of a toppled hotel.
Dramatic video shared on social media shows the man being carried on a stretcher as rescue workers surround him, applauding.
In a separate rescue in the nearby city of Sagaing, a 40-year-old man was pulled from the rubble on Wednesday and is 'doing OK' at a local hospital, a local rescue worker said. Video obtained by CNN shows rescuers using special cameras to locate the man.
The quake killed more than 3,000 people and injured thousands more, according to the ruling junta. Experts have warned the true death toll is likely to be higher as hundreds remain missing and hopes of finding people alive is dwindling fast.
Humanitarian organizations are continuing to stress the need for urgent aid, especially to more remote areas of the country.
Even before the quake, four years of civil war had left millions without adequate shelter, and battered health and communication infrastructure.
It was unclear on Thursday whether the temporary ceasefire set to run until April 22 was holding.
Hospitals are struggling to cope with the overwhelming number of injured, as critical medical care is delivered from makeshift tents, the World Health Organization (WHO) has warned.
'In these tents, patients with fractures, wounds, and shock are being stabilized. They are functioning as mobile health clinics — delivering care where there are no longer walls,' said a WHO emergency team member on site in Mandalay.
Around 500 buildings have totally collapsed and 800 more are partially destroyed, according to Doctors Without Borders (MSF), raising challenges for rescue workers toiling among the rubble.
Junta chief Min Aung Hlaing was scheduled to address the disaster response at a meeting of regional leaders on Thursday in neighboring Thailand, where powerful tremors from the quake killed at least 22 people.
In Thailand's capital Bangkok, rescuers detected signs of life on Thursday at a site where dozens are feared trapped under the rubble following the collapse of an under-construction high rise building that killed at least 15 people.
Bangkok Gov. Chadchart Sittipunt said workers digging through the rubble 'shouted into a shaft' and heard a voice back – raising hopes for families that have faced an agonizing wait for news of their loved ones.
'This signal suggests that someone is there, offering hope,' Chadchart said. 'We are all moving forward with full effort. The operation to drill into the area continues.'
CNN's Kocha Olarn contributed reporting from Bangkok

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Avextra Cannabis extract can potentially reduce symptom burden for late palliative patients
Avextra Cannabis extract can potentially reduce symptom burden for late palliative patients

Yahoo

time2 hours ago

  • Yahoo

Avextra Cannabis extract can potentially reduce symptom burden for late palliative patients

Prof. Dr. med. Sven Gottschling, Principal Investigator for the CORAL study. New Study Demonstrates Significant Symptom Relief for Late-Stage Palliative Patients Treated with Cannabis-based Medicines Bensheim, Germany – 13th June 2025 – According to the World Health Organization, an estimated 56.8 million palliative care patients worldwide suffer from significant symptom burden every year. In palliative care — particularly for oncology patients — effective symptom management is essential to maintaining dignity, comfort, and quality of life in the final stages of illness. Despite advances in conventional therapies, many patients continue to suffer from uncontrolled pain, anxiety, and other distressing symptoms. The CORAL study offers promising evidence that cannabinoid-based medicines may play a critical role in addressing this unmet need. The CORAL study (CannabinOid-TheRapie in der PALliativmedizin or Cannabinoid Therapy in Palliative Care) is a non-interventional, parallel group study designed to examine the reduction of symptom burden in patients receiving end-of-life care. Led by Prof. Dr. med. Sven Gottschling from Universitätsklinikum des Saarlandes in Homburg, 150 patients in advanced palliative stages were enrolled in the study, with over 80% being oncology patients. 100 of them were additionally treated with the cannabis extract Avextra 10:10 (THC/CBD), the other 50 with a non-cannabinoid treatment. Key Findings from the CORAL Study Significant Symptom Reduction: Patients treated with Avextra's extract showed statistically and clinically significant improvement in MIDOS scores (a palliative symptom assessment tool), while the control group's symptoms worsened. 68% of patients treated with Avextra showed clinically relevant improvement (≥20%). Mental Health Improvements: Stress, anxiety, and depression levels (measured by DASS-21) improved in the Avextra group, but worsened in the control group. All were statistically and clinically superior to the control group ; 50% were stress responders, and over 20% improved in all three DASS categories. Quality of Life Gains: Patients reported better outcomes across multiple domains in the EORTC QLQ-C15-PAL questionnaire, a quality-of-life tool validated for palliative care. Nearly 25% of patients in the Avextra group showed clinically relevant quality of life improvement. Lower Co-medication Burden: Avextra-treated patients require significantly less use of sedatives, sleep aids, benzodiazepines, and muscle relaxants. High Tolerability: The extract was well tolerated, with fewer than 15% of patients reporting any adverse reactions and only three dropouts due to side effects. Principal investigator Prof. Dr. Sven Gottschling, Head Physician of the Center for All-Age Palliative Medicine and Paediatric Pain Therapy at the UKS in Homburg, presents the study results during the 6th Medicinal Cannabis Congress in Berlin. He stated: "The CORAL study is another significant contribution to improving the treatment of those with serious, terminal diseases. We would like to thank our study partner Avextra: Together, we are committed to improving symptom burden reduction of those affected and further optimizing palliative care treatment options for patients and caregivers." Enhanced quality of life towards the end of lifeThere is a significant need for interdisciplinary studies, particularly in palliative care. This was highlighted in February by representatives of the Leopoldina (German National Academy of Sciences) and other scientific experts in Berlin. "Avextra's goal is to further improve symptom relief for palliative care patients. We are happy that our products appear to be helping to achieve that, and this motivates us to develop even better, innovative dosage forms for this patient group," said Dr. Bernhard Babel, CEO of Avextra. About Avextra AG Avextra is one of Europe's leading vertically integrated medical cannabis operators focused on the development and production of regulator-approved medicines. Founded in 2019 and based in Germany, the company works in close collaboration with doctors, pharmacists and researchers to develop and produce innovative Cannabis-based Medicines. Avextra controls the entire value chain – from cultivation to EU-GMP certified extraction and manufacturing in Germany. Avextra´s products are distributed in federally regulated cannabis access programmes across Europe. Going forward, Avextra will keep conducting studies focusing on the clinical outcomes of cannabis-based medicines on patients' overall reduction of symptom burden. Clinical trials represent a key element of the German biotech company's strategic focus towards getting a registered medicine. Learn more at and stay up to date at LinkedIn: Avextra Media Enquiries: For media enquiries or to set up an interview please contact: Email: press@ Phone: +49 30 408174037 Attachment Prof. Dr. med. Sven Gottschling, Principal Investigator for the CORAL in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Avextra Cannabis extract can potentially reduce symptom burden for late palliative patients
Avextra Cannabis extract can potentially reduce symptom burden for late palliative patients

Yahoo

time3 hours ago

  • Yahoo

Avextra Cannabis extract can potentially reduce symptom burden for late palliative patients

Prof. Dr. med. Sven Gottschling, Principal Investigator for the CORAL study. New Study Demonstrates Significant Symptom Relief for Late-Stage Palliative Patients Treated with Cannabis-based Medicines Bensheim, Germany – 13th June 2025 – According to the World Health Organization, an estimated 56.8 million palliative care patients worldwide suffer from significant symptom burden every year. In palliative care — particularly for oncology patients — effective symptom management is essential to maintaining dignity, comfort, and quality of life in the final stages of illness. Despite advances in conventional therapies, many patients continue to suffer from uncontrolled pain, anxiety, and other distressing symptoms. The CORAL study offers promising evidence that cannabinoid-based medicines may play a critical role in addressing this unmet need. The CORAL study (CannabinOid-TheRapie in der PALliativmedizin or Cannabinoid Therapy in Palliative Care) is a non-interventional, parallel group study designed to examine the reduction of symptom burden in patients receiving end-of-life care. Led by Prof. Dr. med. Sven Gottschling from Universitätsklinikum des Saarlandes in Homburg, 150 patients in advanced palliative stages were enrolled in the study, with over 80% being oncology patients. 100 of them were additionally treated with the cannabis extract Avextra 10:10 (THC/CBD), the other 50 with a non-cannabinoid treatment. Key Findings from the CORAL Study Significant Symptom Reduction: Patients treated with Avextra's extract showed statistically and clinically significant improvement in MIDOS scores (a palliative symptom assessment tool), while the control group's symptoms worsened. 68% of patients treated with Avextra showed clinically relevant improvement (≥20%). Mental Health Improvements: Stress, anxiety, and depression levels (measured by DASS-21) improved in the Avextra group, but worsened in the control group. All were statistically and clinically superior to the control group ; 50% were stress responders, and over 20% improved in all three DASS categories. Quality of Life Gains: Patients reported better outcomes across multiple domains in the EORTC QLQ-C15-PAL questionnaire, a quality-of-life tool validated for palliative care. Nearly 25% of patients in the Avextra group showed clinically relevant quality of life improvement. Lower Co-medication Burden: Avextra-treated patients require significantly less use of sedatives, sleep aids, benzodiazepines, and muscle relaxants. High Tolerability: The extract was well tolerated, with fewer than 15% of patients reporting any adverse reactions and only three dropouts due to side effects. Principal investigator Prof. Dr. Sven Gottschling, Head Physician of the Center for All-Age Palliative Medicine and Paediatric Pain Therapy at the UKS in Homburg, presents the study results during the 6th Medicinal Cannabis Congress in Berlin. He stated: "The CORAL study is another significant contribution to improving the treatment of those with serious, terminal diseases. We would like to thank our study partner Avextra: Together, we are committed to improving symptom burden reduction of those affected and further optimizing palliative care treatment options for patients and caregivers." Enhanced quality of life towards the end of lifeThere is a significant need for interdisciplinary studies, particularly in palliative care. This was highlighted in February by representatives of the Leopoldina (German National Academy of Sciences) and other scientific experts in Berlin. "Avextra's goal is to further improve symptom relief for palliative care patients. We are happy that our products appear to be helping to achieve that, and this motivates us to develop even better, innovative dosage forms for this patient group," said Dr. Bernhard Babel, CEO of Avextra. About Avextra AG Avextra is one of Europe's leading vertically integrated medical cannabis operators focused on the development and production of regulator-approved medicines. Founded in 2019 and based in Germany, the company works in close collaboration with doctors, pharmacists and researchers to develop and produce innovative Cannabis-based Medicines. Avextra controls the entire value chain – from cultivation to EU-GMP certified extraction and manufacturing in Germany. Avextra´s products are distributed in federally regulated cannabis access programmes across Europe. Going forward, Avextra will keep conducting studies focusing on the clinical outcomes of cannabis-based medicines on patients' overall reduction of symptom burden. Clinical trials represent a key element of the German biotech company's strategic focus towards getting a registered medicine. Learn more at and stay up to date at LinkedIn: Avextra Media Enquiries: For media enquiries or to set up an interview please contact: Email: press@ Phone: +49 30 408174037 Attachment Prof. Dr. med. Sven Gottschling, Principal Investigator for the CORAL in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions
Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions

Yahoo

time7 hours ago

  • Yahoo

Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions

SAN FRANCISCO and SUZHOU, China, June 12, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that it will present multiple clinical study results of mazdutide at the American Diabetes Association's® (ADA) 85th Scientific Sessions in Chicago, U.S. from June 20 -23. Innovent will orally present the first Phase 3 study of mazdutide in Chinese adults with T2D (DREAMS-1). In addition, multiple exploratory MoA analyses of mazdutide as well as preclinical study of IBI3030 (PCSK9-GGG antibody-peptide-conjugate) will be showcased in poster presentations. Details are listed below: Title: Mazdutide vs. Placebo as Monotherapy in Patients with Type 2 Diabetes (DREAMS-1)Abstract #:306-OR Presentation Form: Oral presentationTime: 2025 June 23, 14:15 PM – 14:30 PM(CST)Presenter: Dr. Lei Qian, Innovent Biologics Title: A novel antibody-peptide conjugate targeting PCSK9, GLP-1R, GCGR, GIPR improves cardiovascular risk markers in preclinical studyAbstract #:1886-LBPresentation Form: Poster presentationTime: 2025 June 22, 12:30 PM – 1:30 PM(CST)Presenter: Dr. Decheng Ren, Innovent Biologics Title: The Dual Glucagon and Glucagon-Like Peptide 1 Receptor Agonist Mazdutide Outbalanced Glucagon-Like Peptide 1 Receptor Agonist Semaglutide Monotherapy in Improving Mice Liver Fat AccumulationAbstract #:777-PPresentation Form: Poster presentationTime: 2025 June 22, 12:30 PM – 1:30 PM(CST)Presenter: Hong, Peking University Third Hospital Title: Effect of Mazdutide on MASH Fibrosis – Targeting the Liver-Gut Axis and MicrobiomeAbstract #:1616-P Presentation Form: Poster presentationTime: 2025 June 22, 12:30 PM – 1:30 PM(CST)Presenter: Professor Ling Li, Zhongda Hospital Affiliated to Southeast University Title: Mazdutide, a Dual GLP-1R/GCGRR Agonist, Reduces Hyperuricemia by Modulating Energy and Lipid Metabolism and Inhibiting Hepatic Purine MetabolismAbstract #:775-PPresentation Form: Poster presentationTime: 2025 June 22, 12:30 PM – 1:30 PM(CST)Presenter: Professor Hongwei Jiang, The First Affiliated Hospital of Henan University of Science and Technology Dr. Lei Qian, Vice President of Clinical Development of Innovent, stated, "We are honored to orally present the results of mazdutide's first Phase 3 clinical trial in T2D (DREAMS-1) at the ADA Scientific Sessions. We are also delighted to see mazdutide's mechanism exploration studies featured extensively at the conference. The growing body of medical evidence will further validate mazdutide's differentiated profile as a next-generation GCG/GLP-1 dual receptor agonist, in particularly in liver fat and serum urine reduction. Moreover, in the field of cardiovascular and metabolic diseases, Innovent is dedicated to developing next-generation innovative therapies, including IBI3030(PCSK9-GGG)with novel modality and MoA, to meaningfully improve outcomes for more patients worldwide." About Mazdutide (IBI362) Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide may offer additional benefits beyond those of GLP-1 receptor agonists—such as promoting insulin secretion, lowering blood glucose and reducing body weight—by also activating the glucagon receptor to increase energy expenditure and improve hepatic fat metabolism. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies. It has also shown benefits in reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity. Currently, Mazdutide has two NDAs accepted for review by NMPA, including: Long-term weight management in adults with obesity or overweight. Glycemic control in adults with type 2 diabetes (T2D). Mazdutide is currently being evaluated in six Phase 3 clinical studies, including: GLORY-1: A Phase 3 trial in Chinese participants with overweight or obesity. GLORY-2: A Phase 3 trial in Chinese participants with moderate-to-severe obesity. GLORY-3: A Phase 3 trial comparing Mazdutide and Semaglutide in Chinese participants with overweight/obesity and metabolic dysfunction-associated fatty liver disease (MAFLD). DREAMS-1: A Phase 3 trial in treatment-naïve Chinese participants with T2D. DREAMS-2: A Phase 3 trial comparing Mazdutide and Dulaglutide in Chinese T2D participants with inadequate glycemic control on oral antidiabetic drugs. DREAMS-3: A Phase 3 trial comparing Mazdutide and Semaglutide in Chinese participants with T2D and obesity. Among these, GLORY-1, DREAMS-1, and DREAMS-2 have already met their primary endpoints and others are currently ongoing. In addition, several new clinical studies of mazdutide are planned, including: A Phase 3 trial in adolescents with obesity. New studies in metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF). About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect. View original content: SOURCE Innovent Biologics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store